

Ref: FOI/2025/10881

Date Received: 3rd July 2025

Response Due: 31st July 2025

Date: 29th July 2025

Dear Sir/Madam

With reference to your request for information received on 3rd July 2025, I can confirm in accordance with Section 1 (1) of the Freedom of Information Act 2000 that we do hold the information you have requested. A response to each part of your request is provided below.

In your request you asked:

- 1. In the last 6 months, how many patients have been diagnosed with Diffuse Large B Cell Lymphoma (DLBCL)?**
5.
- 1a. Of these patients, how many commenced treatment at your trust within the last 6 months?**
4.
- 2. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments:**
 - R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone) = 4.
 - R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone) = 0.
 - Pola-BR (polatuzumab vedotin with rituximab and bendamustine) = 0.
 - Pola-R-CHP (Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisolone) = 5.
 - R-CODOX-M (rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate) = 0.
 - R-IVAC (rituximab, ifosfamide, etoposide and cytarabine) = 0.
 - R-GCVP (Rituximab, gemcitabine, cyclophosphamide, vincristine, prednisolone) = 0.
 - (DA)-EPOCH +/-R (Prednisolone, doxorubicin, vincristine, etoposide, cyclophosphamide, rituximab) = 0.
 - R-GemOX (rituximab, gemcitabine and oxaliplatin) = 0.

- **Axicabtagene ciloleucel** = 0.
 - **Tisagenlecleucel** = 0.
 - **Epcoritamab** = 0.
 - **Loncastuximab tesirine** = 0.
 - **Glofitamab** = 0.
 - **Any other SACT** = 1.
 - **Stem cell transplant or bone marrow transplant (autologous or allogeneic)** = 0.
3. In the last 6 months, how many patients have received the following 2nd line treatments for Diffuse Large B Cell Lymphoma (DLBCL):
- **Axicabtagene ciloleucel (Yescarta)** = 0.
 - **Tisagenlecleucel** = 0.
 - **Pola-BR (polatuzumab vedotin with rituximab and bendamustine)** = 0.
 - **R-GemOX (rituximab, gemcitabine and oxaliplatin)** = 0.
 - **Stem cell transplant or bone marrow transplant (autologous or allogeneic)** = 0.
 - **Any other treatments** = 0.
4. In the last 6 months, how many patients has the Trust treated for 3rd line Diffuse Large B Cell Lymphoma (DLBCL)?
0.
5. In the last 6 months, how many patients have you referred to other trusts for the treatment of Diffuse Large B Cell Lymphoma (DLBCL) for the following treatments:
- **CAR-T Therapy (E.g. Axicabtagene ciloleucel)** = 0.
 - **Stem cell transplant or bone marrow transplant (autologous or allogeneic)** = 0.
 - **Any other treatment** = 0.

If you are not entirely satisfied with this response, please do not hesitate to contact the Information Governance Department via the email address provided. If we do not hear from you within 40 days, we will assume that we have been able to accommodate your request under the Freedom of Information Act 2000.

Yours sincerely,



Gary Masterman
Associate Director of Pharmacy (Governance Assurance)

PLEASE NOTE:

If you are unhappy with the service you have received in relation to your request and wish to make a complaint or request a review of our decision, you should write to: Information Governance Department, Wrightington, Wigan and Leigh NHS Foundation Trust, Suite 9, Buckingham Row, Brick Kiln Lane, Wigan, WN1 1XX.

If you are not content with the outcome of your complaint, you may apply directly to the Information Commissioner for a decision at:

The Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire, SK9 5AF

Helpline number: 0303 123 111